The difference between Alnylam and Benitec is the $1b Alnylam has in cash. Also, they have a more advanced pipeline, but in areas that take a long time to evaluate. HBV/HCV are all diseases that can get through clinical trial very quickly. HIV maybe longer, but theoretically, Calimmune may already know if CAL-1 is working.
Alnylam and Benitec hold the lions share of core patents for RNAi. They both have crosslicenced their technologies as well.
- Forums
- ASX - By Stock
- BLT
- cashed up, ready to make medical history
cashed up, ready to make medical history, page-23
-
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online